IN8BIO, Inc.

INAB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001740279

SEC filings (opens in a new tab)

No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding IN8BIO, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026 All holders in Q1 2026

13F holders of INAB: Q1 2026 compared with Q2 2026
Measure	Q1 2026	Q2 2026	Change
Holders	19	21	+2
Shares	3.75M	3.79M	+37.0K (+1.0%)
Value	$5.55M	$5.35M	−$209.3K (−3.8%)

New holders (3)

Institutions that held IN8BIO, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to INAB in Q2 2026
Institution	Shares	Value	% of portfolio
Citadel Advisors LLC	63,055	$88.9K	0.00%
Renaissance Technologies LLC	12,100	$17.1K	0.00%
Barclays PLC	28	$39	0.00%

Sold out (1)

Institutions that held IN8BIO, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of INAB in Q2 2026
Institution	Shares, Q1 2026	Value, Q1 2026
XTX Topco Ltd	12,433	$18.4K